PMID- 20666849
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20220316
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 64
IP  - 11
DP  - 2010 Oct
TI  - Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by 
      soft tissue injury.
PG  - 1546-1553
LID - 10.1111/j.1742-1241.2010.02474.x [doi]
AB  - Acute pain caused by musculoskeletal disorders is very common and has a 
      significant negative impact on quality-of-life and societal costs. Many types of 
      acute pain have been managed with traditional oral non-steroidal 
      anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors 
      (coxibs). Data from prospective, randomised controlled clinical trials and 
      postmarketing surveillance indicate that use of oral traditional NSAIDs and 
      coxibs is associated with an elevated risk of developing gastrointestinal, 
      renovascular and/or cardiovascular adverse events (AEs). Increasing awareness of 
      the AEs associated with NSAID therapy, including coxibs, has led many physicians 
      and patients to reconsider use of these drugs and look for alternative treatment 
      options. Treatment with NSAIDs via the topical route of administration has been 
      shown to provide clinically effective analgesia at the site of application while 
      minimising systemic absorption. The anti-inflammatory and analgesic potency of 
      the traditional oral NSAID diclofenac, along with its physicochemical properties, 
      makes it well suited for topical delivery. Several topical formulations of 
      diclofenac have been developed. A topical patch containing diclofenac epolamine 
      1.3% (DETP, FLECTOR((R)) Patch), approved for use in Europe in 1993, has recently 
      been approved for use in the United States and is indicated for the treatment of 
      acute pain caused by minor strains, sprains and contusions. In this article, we 
      review the available clinical trial data for this product in the treatment of 
      pain caused by soft tissue injury.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - McCarberg, B H
AU  - McCarberg BH
AD  - Kaiser Permanente Health Care, Chronic Pain Management Program, Escondido, CA, 
      USAComprehensive Pain Program, Department of Neurology, Albany Medical Center, 
      Albany, NY, USA.
FAU - Argoff, C E
AU  - Argoff CE
AD  - Kaiser Permanente Health Care, Chronic Pain Management Program, Escondido, CA, 
      USAComprehensive Pain Program, Department of Neurology, Albany Medical Center, 
      Albany, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 119623-66-4 (diclofenac hydroxyethylpyrrolidine)
RN  - 144O8QL0L1 (Diclofenac)
SB  - IM
MH  - Analgesics/*administration & dosage/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/pharmacology
MH  - Contusions/complications/drug therapy
MH  - Diclofenac/administration & dosage/adverse effects/*analogs & derivatives
MH  - Humans
MH  - Pain/etiology/*prevention & control
MH  - Soft Tissue Injuries/complications/*drug therapy
MH  - Sprains and Strains/complications/drug therapy
MH  - Transdermal Patch
MH  - Treatment Outcome
PMC - PMC2984542
EDAT- 2010/07/30 06:00
MHDA- 2011/12/13 00:00
CRDT- 2010/07/30 06:00
PHST- 2010/07/30 06:00 [entrez]
PHST- 2010/07/30 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1111/j.1742-1241.2010.02474.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2010 Oct;64(11):1546-1553. doi: 
      10.1111/j.1742-1241.2010.02474.x.